Pathology consultation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia

American Journal of Clinical Pathology

Volumn 139, Issue 6, 2013, Pages 708-712

  Siddon, Alexa J ^a   Rinder, Henry M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD38; Chronic lymphocytic leukemia; IGHV somatic hypermutation; Monoclonal B cell lymphocytosis; Prognosis; Survival; TP53 mutation; ZAP 70

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; PROTEIN KINASE ZAP 70; PROTEIN P53;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; MALE; MONOCLONAL B CELL LYMPHOCYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRISOMY 12;

CD38; CHRONIC LYMPHOCYTIC LEUKEMIA; IGHV SOMATIC HYPERMUTATION; MONOCLONAL B-CELL LYMPHOCYTOSIS; PROGNOSIS; SURVIVAL; TP53 MUTATION; ZAP-70;

ANTIGENS, CD38; BETA 2-MICROGLOBULIN; FLOW CYTOMETRY; GENE REARRANGEMENT, B-LYMPHOCYTE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; INCIDENTAL FINDINGS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTOSIS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; WATCHFUL WAITING; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84878394241     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPLIR4GZWX3XKA     Document Type: Article

References (38)

1. Dores GM, Anderson WF, Curtus RE, et al. Chronic lymphocytic leukemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007;139:809-819. (Pubitemid 350115721)
2. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008.
3. Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B cell lymphocytosis. Br J Haematol. 2005;130:325-332. (Pubitemid 43899581)
4. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 Guidelines. Blood. 2008;111:5446-5456.
5. Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002;100;635-639. (Pubitemid 34761129)
6. Landgren O, Albitar M, Ma W, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 2009;360:659-667.
7. Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359:575-583.
8. Rossi D, Sozzi E, Puma A, et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biologic risk factors. Br J Haematol. 2009;146:64-75.
9. Fazi C, Scarfo L, Pecciarini L, et al. General population low-count CLL-like MBL persist over time without clinical progression, though carrying the same cytogenetic abnormalities of CLL. Blood. 2011;118:6618-6625.
10. Ghia P, Caligaris-Cappio F. Monoclonal B-cell lymphocytosis: right track or red herring? Blood. 2012;119:4358-4362.
11. Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:50-54.
12. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.
13. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206. (Pubitemid 11064396)
14. Letestu R, Levy V, Eclache V, et al. Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood. 2010;116:4588-4590.
15. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood. 1999;93:1732-1737. (Pubitemid 29102502)
16. Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood. 2011;118:2821-2826.
17. Morabito F, De Filippi R, Laurenti L, et al. The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood. 2011;118:6353-6361.
18. Wierda WG, Johnson MM, Do KA, et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukemia. Br J Haematol. 2003;120:452-456. (Pubitemid 36241501)
19. Stamatopoulos B, Meuleman N, Haibe-Kains B, et al. microRNA-29c and microRNA-223 downregulation has an in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009;113:5237-5245.
20. Visone R, Rassenti LZ, Veronese A, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009;114:3872-3879.
21. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854. (Pubitemid 29430400)
22. Damle RN, Wasil T, Fais F, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847. (Pubitemid 29430399)
23. Hamblin TJ, Orchard JA, Gardiner A, et al. Immunoglobulin V genes and CD38 expression in CLL. Blood. 2000;95:2455-2457. (Pubitemid 30167754)
24. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001;98:2633-2639.
25. Morabito F, Mangiola M, Stelitano C, et al. Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil. Haematologica. 2002;87:217-218. (Pubitemid 34160629)
26. Zenz T, Gribben JG, Hallek M, et al. Risk categories and refractory CLL in the era of chemotherapy. Blood. 2012;119:4101-4107.
27. Damle RN, Temburni S, Calissano C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood. 2007;110:3352-3359. (Pubitemid 350106329)
28. Malavasi F, Deaglio S, Damle R, et al. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011;118:3470-3478.
29. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775. (Pubitemid 36514707)
30. Weistner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951. (Pubitemid 36857758)
31. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901. (Pubitemid 39096916)
32. Chen YH, Peterson LC, Dittman D, et al. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVh mutational status in chronic lymphocytic leukemia. Am J Clin Pathol. 2007;127:182-191. (Pubitemid 46797174)
33. Wang YH, Fan L, Xu W, et al. Detection methods of ZAP-70 in chronic lymphocytic leukemia. Clin Exp Med. 2012;12:69-77.
34. Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukemia. Nat Rev Cancer. 2010;10:37-50.
35. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-2229.
36. Sellner L, Dietrich S, Dreger P, et al. Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia? Curr Hematol Malig Rep. 2012;7:3-12.
37. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011;29:2223-2229.
38. Gribben JG. How I treat CLL up front. Blood. 2010;115:187-197.